Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation by Thompson, JE et al.
RESEARCH ARTICLE Open Access
Peri-operative, functional and early
oncologic outcomes of salvage robotic-
assisted radical prostatectomy after high-
intensity focused ultrasound partial
ablation
James E. Thompson1,2* , Ashwin N. Sridhar1,3, Greg Shaw1,3, Prabhakar Rajan1,4, Anna Mohammed1,
Timothy P. Briggs1, Senthil Nathan1,3, John D. Kelly1,3 and Prasanna Sooriakumaran1,3,5
Abstract
Background: Partial ablation of the prostate using high-intensity focussed ultrasound (HIFU-PA) is a treatment
option for localised prostate cancer. When local recurrence occurs, salvage robot-assisted radical prostatectomy is a
treatment option for selected patients, but there is a paucity of data on the peri-operative safety, functional and
oncologic outcomes of sRARP..
The objective of this study was therefore to describe peri-operative safety, functional and early oncologic outcomes
following salvage robot-assisted radical prostatectomy (sRARP) for local recurrence after HIFU-PA.
Methods: Retrospective analysis of a prospective database of 53 consecutive men who underwent sRARP after
HIFU-PA from 2012 to 2018. Continence and erectile-function were reported pre-HIFU, pre-sRARP, 3-months post-
sRARP and 12-months post-sRARP. Complications, PSMs and need for subsequent ADT/radiotherapy were assessed.
Results: 45 men were suitable for inclusion and had sufficient data for analyses. Median duration from HIFU to
sRARP was 30.0 months and median follow-up post-sRARP was 17.7 months. Median age, PSA and ISUP group were
63.0 yrs., 7.2 ng/mL and 2; 88.9% were cT2.
Median operative-console time, blood loss and hospital stay were 140min, 200ml and 1 day respectively. Clavien-Dindo
grade 1, 2 and 3 complications < 90 days occurred in 8.9, 6.7 and 2.2%; late (>90d) complications occurred in 13.2%.
At sRARP pathology, ISUP 3–5 occurred in 51.1%, pT3a/b in 64.5%, and PSMs in 44.4% (37.5% for pT2, 48.3% for pT3).
Of men with > 3-months follow-up after sRARP, 26.3% underwent adjuvant radiotherapy/ADT for residual disease or
adverse pathologic features; 5.3% experienced BCR requiring salvage ADT/radiotherapy. Freedom from ADT/radiotherapy
was 66.7% at 12-months.
Pad-free rates were 100% pre-HIFU, 95.3% post-HIFU, 29.4% 3-months post-sRARP, and 65.5% 12-months post-sRARP.
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Median IIEF-5 scores pre-HIFU, post-HIFU, 3- and 12-months post-sRARP were 23.5, 16, 5 and 5, respectively. Potency rates
were 81.8, 65.5, 0 and 0%, respectively. Bilateral/unilateral nerve sparing were feasible in 7%/22%.
Conclusion: Salvage RARP was safe with acceptable but sub-optimal continence and poor sexual-function and poor
oncologic outcomes. One in three men required additional treatment within 12-months. This information may aid men
and urologists with treatment selection and counselling regarding primary HIFU-PA vs primary RARP and when
considering salvage RARP.
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Background
Partial Ablation (PA) is proposed as a less morbid alter-
native to radical therapy for localized prostate cancer
[1]. High-intensity focused ultrasound (HIFU) is one of
several ablative modalities that have been approved for
clinical use within prospective registry studies in the UK
[2], although it remains experimental according to inter-
national guidelines [3, 4]. Evidence of oncologic efficacy
for HIFU-PA is limited to observational cohorts with
short follow-up, using PSA or radical treatment-free sur-
vival endpoints and without comparison to a matched
group undergoing radical treatment [1, 5, 6].
Prostate cancer is often multi-focal and thus local re-
currence after PA is common; 37–41% experienced re-
currence requiring further treatment within 5 years and
more than half (54%) by 8-years in two large, multi-
centre series [6, 7], despite the fact that only a third
underwent biopsy after HIFU; the rate of recurrence
may therefore increase with longer follow-up.
There is very little published data on outcomes for sal-
vage RARP after HIFU-PA. sRARP after radiotherapy is
associated with adverse pathologic features, high PSM
rates, low continence rates, poor erectile function and
higher anastomotic leak/stricture rates compared to pri-
mary RARP [8–10]. After PA, Nunes-Silva et al. reported
similar continence but worse sexual function and higher
recurrence rates for sRARP compared to primary RARP
in a matched-pair analysis [11]. Marconi et al. recently
reported on their cohort of 82 men undergoing sRARP
after FA by two surgeons in which they demonstrated
safety and feasibility as well as impressive 83% pad-free
continence at 1 year; however, potency was low (14% at
1 year) and the incidence of BCR was high (64% at 3-
years) [12].
The most commonly used PA modality in the UK is
HIFU and yet there are presently no published cohorts
reporting on sRARP purely after HIFU-PA. This limits
treatment selection and pre-treatment counselling for
men with local recurrence after HIFU-PA or considering
HIFU-PA as primary therapy.
We recently reported detailed pathologic outcomes in
a series of 35 men and found high rates of multifocal
cancer, Gleason upgrading, locally advanced (pT3a/b)
cancer and positive margins, with a high rate of pT3 re-
currence in-field and most PSMs being in-field due to
the challenges of dissecting microscopic T3 cancer when
it was densely fibrotic to the neurovascular bundles, pel-
vic floor muscles and rectum [13]. The primary objective
of the present study was therefore to describe peri-
operative, oncologic and functional outcomes of sRARP
following HIFU-PA.
Methods
Study design and participants
Shortly after commencing sRARP procedures for recur-
rence post-HIFU, the Department of Pelvic Uro-
Oncology at UCLH established a prospectively main-
tained electronic database to audit and analyse safety,
oncologic and functional outcomes of sRARP post-
HIFU. Data is collected and entered in real-time by a
team of clinical nurse specialists and research fellows,
using a combination of medical records, pathology re-
ports and validated questionnaires. This is the first com-
prehensive analysis reporting all of these outcomes from
this database.
53 men underwent sRARP after focal therapy from
January 2012–August 2017 at our institution. Data on
the exact number of men who underwent focal HIFU up
until 2017 was not available to the authors to ascertain a
precise estimate of recurrence, but a recent study from
two institutions (including ours) reported on outcomes
for 1032 men who underwent focal HIFU over 2005–
2017 [7]. Some of the men in that cohort study under-
went salvage RARP at other institutions for which the
results of sRARP are published elsewhere [12]; therefore
the aforementioned cohort study is better able to assess
the incidence of failure and salvage treatment than the
present cohort.
We excluded 8 men, because including men with bilat-
eral cancer (3 whole-gland HIFU) and ablative technolo-
gies that have dissimilar tissue effects (5 had other
ablative modalities, i.e. cryotherapy or RFA) may other-
wise have confounded outcomes. Median (IQR) follow-
up was 17months (IQR 15.4–20.5) after sRARP and
46.4 months (IQR 33.6–68.6) after HIFU. 33 men had
≥12-months follow-up.
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Eligibility/selection for HIFU
All men had MRI and biopsy confirming prostate cancer
and were deemed suitable for PA via MDT; most were
‘ideal’ candidates in line with prospective study protocols
[14] or expert consensus criteria [15, 16]: PSA ≤15 ng/
mL; ISUP grade group 1–3; cT2; uni-focal on MRI and
biopsy; all were considered suitable for HIFU-PA at the
time of treatment. On retrospective evaluation by the
focal therapy team, however, 19/45 were not ‘ideal’ or
received sub-optimal treatment according to (i) subse-
quently refined selection criteria or (ii) anatomic relative
contra-indications (e.g. large gland, anterior/ apical loca-
tion, capsular abutment suspicious for EPE) or (iii) tech-
nical treatment problems (e.g. probe problems,
prominent calcifications, suboptimal Uchida changes
suggesting incomplete ablation).
Interventions and follow-up post-HIFU
All HIFUs were performed as part of UK-wide registry
or NCRI studies [2] using the Sonoblate 500® device
(Sonacare Medical, North Carolina). Our monitoring
protocol following HIFU was described previously [14],
including 3-monthly PSA, 6–12 month MRI and tar-
geted/ template biopsy for abnormal MRI.
Selection criteria for sRARP
Given this is a retrospective analysis, no prospective se-
lection criteria were defined. General selection criteria
for sRARP were:
 Unsuitable for redo FA (e.g. bilateral/ high-risk can-
cer) or preference towards radical treatment;
 Age < 75yo and fit for major surgery;
 T1-3aN0M0, surgically resectable on MRI and DRE;
 Accepting of risks and side effects of surgery.
Pre-operative imaging included pre-biopsy MRI rou-
tinely, then bone scan and/or Ga68-PSMA PET CT for
high-risk patients.
Salvage RARPs were performed by experienced sur-
geons (> 250 primary RARPs); biopsies and sRARP hist-
ology was reported by sub-specialist uro-pathologists
using 5 mm axial step-sectioning with apical and basal
shaves.
Outcomes evaluated
Clinical, imaging and pathologic characteristics (pre-
HIFU, pre-sRARP, and post-sRARP) were collected.
PSM rates were reported overall and stratified by pT-
stage, focality (single vs multifocal), length (< 3 vs ≥3
mm) and relation to ablation zone (in-field versus out-
of-field). Clinically ‘significant’ margin was defined as
pT3 PSM or ≥ 3 mm length or multifocal.
For post-sRARP oncologic outcomes:
(i) Residual biochemical disease was defined as PSA
≥0.2 ng/mL and rising on successive measurements
without postoperative PSA nadir < 0.2 ng/ml;
(ii) BCR was defined as no residual biochemical disease
followed by a PSA ≥0.2 ng/mL and rising on 2
successive measurements.
(iii)Adjuvant treatment was defined as initiation of
ADT/RT for high-risk pathologic features or re-
sidual biochemical disease;
(iv) Salvage treatment was defined as initiation of ADT/
RT for BCR.
Peri-operative parameters were extracted from oper-
ation reports and discharge summaries. Complications
were attained from discharge summaries, clinic letters,
emergency department records and urology nurse phone
calls after sRARP. Complications were classified using
the Clavien grading system as early (< 90 days) or late
(90–365 days).
Continence and sexual function data were extracted
from prospective questionnaires by independent re-
searchers/nurse specialists. Pre- and post-HIFU-PA,
leak-free and pad-free status were assessed via EPIC-
QOL. After sRARP at 3- and 12-months, continence
outcomes (number of pads/24 h) were assessed via
ICIQ-SF. Primary sexual function variables were IIEF-5
score (5–25) and Q2 of the EPIC/IIEF sexual function
domain, i.e. “how often are erections firm enough for
sexual intercourse” (1–5: 1 = none, 3 = half, 5 = all of the
time). Q2 responses 3–5 were defined as potent for bin-
ary endpoint analysis. PDE5 inhibitors were permitted
but men requiring invasive erectile aids were classified
as impotent.
Results
CLINICO-PATHOLOGIC CHARACTERISTICS (pre-HIFU, pre-
and post-sRARP)
Clinico-pathologic characteristics pre-HIFU, pre-sRARP
and post-sRARP are shown in Table 1 including age,
PSA, Gleason sum, cancer volume and cT-stage.
HIFU treatment details are shown in Table 2 including
the proportion who were ideal in retrospect according to
consensus selection criteria, type of biopsy pre-HIFU the
anatomic extent of the ablation field in each patient, the
number of treatments and presence of low-grade cancer
left untreated.
Median time from diagnosis to sRARP was 43-months
(IQR 30–67); median time from last HIFU to sRARP
was 30-months (IQR 18–63).
PERI-operative outcomes and complications
Peri-operative outcomes and complications are shown in
Table 3. Median (IQR) operative-console duration was
140 min (120–180). Median (IQR) blood loss was 200ml
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(100–300). Median (IQR) length of stay was 1 day (1–2).
The incidence of early (< 90 days) Grade 1, 2 and 3 com-
plications were 8.9, 6.7 and 2.2%, respectively; the inci-
dence of late (90–365 days) post-operative complications
requiring re-admission was 15.2% (Table 3).
Oncologic outcomes
The overall (clinically significant) PSM rate was 44.4%
(26.3%), with 81% PSMs being in-field. The pT2 over-
all (clinically significant) margin rate was 37.5%
(12.5%), with 83.3% PSMs being in-field. The pT3
Table 1 – Comparative clinico-pathologic characteristics pre-HIFU, pre-sRARP and post-sRARP (n = 45)
Variables Pre-HIFU Pre-sRARP Final sRARP pathology
Age, years (IQR) 62 (IQR 60–66) 63.0 yrs. (IQR 61–66) –
PSA, median (IQR) 7.3 (5.5–8.9) 6 (3.9–10.0) –
Gleason score, n (%):
3 + 3 9 (20.0) 3 (6.7) 0 (0)
3 + 4 29 (64.4) 22 (48.9) 22 (48.9)
4 + 3 (or 3 + 4 with tertiary grade 5) 5 (11.1) 15 (33.3) 18 (40.0)
4 + 4 (or 4 + 3 with tertiary grade 5) 2 (4.4) 2 (4.4) 1 (2.2)
4 + 5 – 3 (6.7) 4 (8.9)
T-stage*, n (%):
T2 43 (95.6) 40 (88.9) 16 (35.6)
T3a 2 (4.4) 4 (8.9) 21 (46.7)
T3b – 1 (2.2) 8 (17.8)
Max cancer core length in mm, median (IQR) 7 (5–10) 6 (3–8) n/a
Number of cores taken, median (IQR) 36 (14–58) 13 (8–24) n/a
Percentage of positive cores, median (IQR) 17 (11–30) 30 (14–40) n/a
Table 2 – HIFU treatment technical details (n = 45)
Ideal according to consensus criteria, n (%) 26 (57.8)
Prostate volume, median (IQR) 35 (27–46)
Location of treatment (combined treatment fields for n = 5 with 2 HIFU treatments)
Hemi-gland unilateral
Hemi-gland with extension across midline or into SV 16
Hemi-gland anterior 7
Hemi-gland posterior 1
Quadrant (e.g. unilateral posterior) 1
Focal ablation (eg posterior right basal segment) 13
Subtotal (extended hemi-ablation, sparing lateral aspect of contralateral side) 6
1
Number of HIFU treatments
1 37
2 8
Known ‘insignificant’ cancer left untreated at HIFU
Yes 21 (47.7)
No 23 (52.3)
Type of biopsy pre-HIFU:
TTMB TP 5mm Mapping + MRI-Targeted (if targets) 24 (53.3)
12–20 core TRUS + MR-targeted (if targets) 17 (37.8)
Targeted alone 3 (6.7)
Not documented 1 (2.2)
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positive margin rate was 48.3%, with 85.7% PSMs be-
ing in-field.
HIFU-PA did not appear to compromise oncologic
outcomes in the out-of-field regions. The rate of out-of-
field (OOF) PSMs was very low, i.e. 6% for pT2 (17%
OOF of 37.5% with PSM) and 7% for pT3 (14% OOF of
48% with PSM). This suggests that the effects of HIFU-
PA on tissues away from the ablation zone were limited,
such that surgeons were able to perform precise surgical
dissection and also this suggests that tumour volumes
may have been low in OOF regions, further reducing the
probability of a PSM.
38 men had 3-month post-RP PSA data; 15.8% of men
had residual biochemical disease (BCD) requiring imme-
diate adjuvant ADT/RT; and additional 5.3% (2/38) re-
ceived early adjuvant ADT + RT due to high risk
features (both pT3a/b + ISUP 3–5 + PSM) and the re-
mainder were managed expectantly; 10.5% (4/38) experi-
enced BCR requiring salvage ADT/RT (three within 12
months, one at 18 months). Of men with minimum 12-
month follow-up or having reached the ADT/RT event
endpoint, 66.7% (22/33) were free from BCR and any ad-
juvant/salvage therapy at 12 months and 63.6% (21/33)
at last follow-up (median 18-months). No men experi-
enced local/distant clinical recurrence or died during
follow-up.
Continence outcomes
44/45 men had 3-month pad-free status documented
(n = 1 with missing data due to failure to attend follow-
up). 2 additional men were excluded from post-sRARP
analysis due to using pads pre-sRARP for urge incontin-
ence. At 3 (12) months post-sRARP, 33.3% (65.5%) were
pad-free and 61.9% (86.2%) were socially continent, re-
spectively. 3 & 12-month median (IQR) ICIQ-scores
were 4 (IQR 0–9) and 0 (0–3), respectively.
Feasibility of nerve sparing at SRARP post-HIFU
At sRARP, unilateral (bilateral) nerve sparing was feas-
ible in 22.2% (6.7%); 11.1% of all NVBs (45 men × 2
NVBs per patient) were preserved. Nerve sparing was
not feasible due to HIFU-induced NVB fibrosis in 60.8%,
suspicion of posterolateral EPE on MRI or high-grade
cancer near the NVB in 23.0% and erectile dysfunction
in 17.9%.
Sexual function outcomes
90.9% (40/44) were potent pre-HIFU based on Q2 EPIC,
IIEF-5 and/or clinical notes documentation of erectile-
function; 73.0% were potent post-HIFU. No man (0/31)
recovered erectile-function at 3 or 12-months post-
sRARP
PENTAFECTA outcomes in men with at least 12-months
follow-up
No man achieved the composite pentafecta [17] out-
come, defined as all of: (i) potent adequate for inter-
course half the time or more with/ without PDE5Is; (ii)
continent not requiring any daily pad use; (iii) free from
BCR; (iv) negative surgical margins; and (v) free from
early or late peri-operative complications. 8/29 (27.6%)
achieved optimal outcomes across the four domains ex-
cluding potency.
Table 3 - Early and Late complications after sRARP according to Clavien group (n = 45)
Early complications (< 90 days) Number (%) Description
Grade I 4 (8.9%) (i) 1x AKI (self-limiting)
(ii) 3 asymptomatic leaks on initial cystogram requiring prolonged catheterisation
Grade 2 3 (6.7%) (i) 1x UTI 2 weeks post-op requiring oral antibiotics;
(ii) 1x readmission for anastomotic leak and fever requiring IV antibiotics and
observation (no intervention)
(ii) 1x transfusion for retroperitoneal bleeding (did not require surgical/ radiologic intervention)
Grade 3a
Grade 3b
1 (2.2%) 3b: Laparotomy, evacuation of clot and re-fashinoing of vesico-urethral anastomosis for
haematoma causing anastomotic leak/ disruption
Grade 4 0 –
Grade 5 (Death) 0 –
Total 8/45 (17.8%) –
Late complications
(90 days – 12months)*
5/33 (15.2%) (i) 3x bladder neck contractures requiring 1 or more cystoscopy + optical dilation
(ii) 1x Hemolock clip protruding into anastomosis causing LUTS
(iii) 1x Small bowel obstruction (resolved with conservative management) due to
adhesions in the same man who underwent laparotomy < 90 days.
*Note to Table: All 45 men completed 90-day peri-operative outcome follow-up; 12 men have not yet reached 12-months follow-up and therefore the sample size
is n = 33
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Descriptive comparison to primary RARP outcomes
Table 4 compares our published primary RARP out-
comes [18, 19] to our salvage RARP outcomes detailed
herein.
Discussion
To our knowledge, this is the second largest reported
cohort of sRARP after PA and the first report on clinical
outcomes purely using HIFU-PA as the ablative modality
(Marconi et al. and Nunes-Silva et al. included a variety
of PA ablative techniques). We found that sRARP is
technically feasible, reasonably safe, and has acceptable
continence outcomes long-term. However, erectile-
function recovery and oncologic results were poorer
than expected for a cohort whom started out with
favourable disease, and continence outcomes are
arguably not ideal. These results are consistent with the
recent report by Marconi et al [12], with the exception
that in the present study the continence rate was lower
(66% vs 83%) and the significant PSM rate was higher
(26% vs 13%), possibly as a result of a greater proportion
of focal re-treatments pre-sRARP in our series.
In this cohort study, sRARP had acceptable periopera-
tive outcomes overall, but with higher than expected
rates of anastomotic leaks and bladder neck contrac-
tures; this may be due to HIFU-induced tissue damage
to the bladder neck and/or urethra in some cases. A re-
cent report suggests that tissue-scaffold bio-grafts may
help reduce the risk of leaks in salvage cases [20]. The
apparently worse continence outcomes compared to pri-
mary RARP in our series, also seem unfavourable com-
pared to the report from Nunes-Silva et al [11], possibly
Table 4 Summary of primary versus salvage RARP outcomes at our institution
Baseline or Outcome Variable Primary RARP(16, 17) Salvage RARP
Complication rate (Clavien-Dindo grade) (%)
Early Grade 1–3 7–13 17.8
Early Grade 4 0.4* 0
Early Grade 5 0* 0
Anastomotic leak on cystogram 2* 11.1
Late bladder neck contracture/ clip 0.5* 10.5














Pad-free at 3-months 67 33.3
Pad-free at 12-months 85.4 65.5
Socially continent at 12-mo (0–1 pad) 89.2 86.2
Proportion where nerve-sparing (NS) feasible
Feasibility of bilateral NS (%) 18 6.7
Feasibility of unilateral NS (%) 34 22.2
Feasibility of bilateral NS in high-risk Ca 10 0.0
Proportion who received bilateral nerve-sparing and were potent at 12-months (potent pre-RARP)# 70 0 (0/2)
*Institutional audit data from latest institutional audit for calendar year 2017, n = 605 primary RARPs; #defined as erections adequate for intercourse at least half
the time with or without the aid of PDE5Is
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due to unmeasured differences in patient characteristics,
extent of PA tissue damage or sRARP surgical technique.
Further studies will provide a larger evidence base for
continence outcomes of sRARP following HIFU, thus we
are participating in a multi-institutional study (RAFT,
NIH trial NCT03011606).
Sexual function outcomes in our series were poor,
with bilateral nerve sparing rarely feasible due to a com-
bination of post-HIFU fibrosis, cancer factors and erect-
ile dysfunction. Potency preservation cannot thus be a
realistic aim of sRARP. The PSM rate was high in this
cohort (44.4% overall, 37.5% pT2 and 48.3% pT3) despite
wide excision at the site of previous HIFU and any high-
grade or capsular tumor; this compares unfavorably to a
recent report for primary RARP from our institution
(17.3% overall, 9.6% pT2 and 26.1% pT3). Likewise, in a
meta-analysis of over 400,000 cases, the pT2 and pT3
PSM rates were 11 and 37% [21]. PSM rates for sRARP
after HIFU-PA were similar to salvage post-radiation
[22], representing technical difficulty dissecting post-
HIFU tissue planes with severe fibrosis/adherence to the
rectum and/or pelvic floor after HIFU.
Early oncologic outcomes were worse than expected
for a selected population who at baseline mostly had
unifocal, intermediate risk, cT2 disease. 1 in 3 men re-
quired further salvage therapy within 12months. This is
consistent with the matched-pair analysis of salvage ver-
sus primary RARP by Nunes-Silva et al. and the Marconi
et al. cohort, which both reported high BCR rates in sal-
vage cohorts. It might arguably be best to therefore per-
form wide bilateral excision in all sRARP cases after PA
in an attempt to gain better oncologic control, especially
as the potency recovery in these men is poor. The poor
outcomes of sRARP vs primary RARP need to be bal-
anced against the fact that in the short-term, propensity
score-matched analysis suggest primary HIFU-PA has
superior continence and potency outcomes to primary
RARP, albeit with a significant risk of requiring salvage
treatment [23, 24].
Our oncologic results were similar to sRARP following
radiotherapy where one-third experience BCR within 12
months [25], half by 5 years [22] and almost two-thirds
by 10 years [26]. It must be stressed, however, that these
salvage RARP cohorts represent a minority of all primary
HIFU cases and this study did not aim to estimate the
incidence of failure after primary HIFU. As a guide, ap-
proximately 1000 focal HIFUs have been performed at
UCLH between 2005 and 2017; 50 sRARPs were per-
formed at UCLH, 20 elsewhere (via the RAFT study), 50
underwent radiotherapy at UCLH (others elsewhere),
some received watchful waiting/ ADT and ~ 20% were
re-treated with HIFU. Therefore, whilst quantifying the
recurrence rate is difficult outside of prospective studies,
we estimate 35–40%, consistent with 37–41% reported
by Guillaumier et al. and Stabile et al., in which 12% re-
quired radical treatment/ADT and another 25% received
redo HIFU within 5 years [6], and 20% required radical
therapy within 8 years [7].
Longer-term follow-up data is only available for whole
gland HIFU; in two multi-centre registry study including
cases from our institution, 37–41% required further
therapy by 5 years and 54% by 8 years [7, 27], while an-
other study reported 60% recurrence for intermediate-
risk and 100% recurrence for high-risk disease by 10
years [28]. These studies suggest that the long-term (10–
15 year) risk of requiring radical therapy after HIFU may
be higher than short-term studies suggest. Hence, we ad-
vise caution in patient selection and counselling until
long-term follow-up data are available for men undergo-
ing PA, especially for those at higher risk of recurrence
e.g. ISUP group 3–5, younger age, family history, or
Afro-Caribbean ethnicity. Our findings that the majority
of recurrences were in-field and apical/ anterior suggest
that other relative contra-indications may include apical
or anterior tumours and large glands. Finally, any indica-
tion of sub-optimal ablation at the time of treatment
(e.g. probe issues, anatomic issues, heavy calcification,
reduced Uchida changes, inadequate treatment effects
on post-HIFU MRI, etc. should warrant early re-biopsy
and consideration of early salvage radical treatment.
This study has limitations. Data collection was pro-
spective, but study design and analyses were retrospect-
ive. Non-standardized patient selection, pre-HIFU and
post-HIFU biopsy techniques and selection for sRARP
preclude from drawing conclusions about the efficacy of
primary HIFU. Furthermore, this study cohort repre-
sents only a small subset of the overall HIFU cohort.
Standardized validated questionnaires were used wher-
ever possible to assess continence and erectile-function,
but some men had missing baseline or follow-up ques-
tionnaires and thus binary endpoints using data from
the medical case notes were relied upon. To minimize
bias, we utilized only data that were collected independ-
ently by a third party (clinical nurse specialist or inde-
pendent erectile dysfunction/incontinence clinic sub-
specialist urologist) in our analyses. Finally, although we
made comparisons to our primary RARP cohort to pro-
vide context to our results, these were unadjusted for
baseline variables. Hence, further studies with matched-
pair analyses of salvage versus primary RARP are re-
quired to validate our findings.
Men who choose HIFU-PA as initial therapy for their
localized prostate cancer do so to avoid the adverse ef-
fects of radical therapy. Given the recurrence rates of
HIFU-PA, it is important these men are adequately
counselled on outcomes of salvage radical therapy
should their disease recur. For a proportion of men con-
sidering this novel therapy, the standard-care option of
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radical prostatectomy may become preferable given the
data herein. Further, with recent innovations in RARP
such as Retzius-sparing [29], which has been shown to
decrease functional compromise, the incremental func-
tional benefits of HIFU-PA over RARP may be reduced.
Standard-care options of management for locally-
recurrent prostate cancer in men after HIFU-PA are
poorly defined, since HIFU-PA as initial therapy is not
itself considered standard-care [3, 4]. Salvage options
vary from systemic therapy to local radical therapy.
sRARP is utilized by many high-volume expert RARP
centres, and our data suggest that even in an experi-
enced centre, overall outcomes are disappointing.
Whether salvage radiotherapy provides better outcomes
is unknown and is under investigation at our institution.
Conclusions
Salvage RARP for recurrent prostate cancer after HIFU-
PA is safe and feasible. Erectile recovery, continence re-
covery cancer recurrence and anastomotic stricture
rates, however, appear worse than for primary RARP.
HIFU-PA is an attractive choice to avoid the morbidity
of radical treatment, but patients and their clinicians
should consider the sub-optimal outcomes of sRARP
when making initial and salvage treatment choices.
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